{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:14Z","timestamp":1753891874571,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Patients with hematological malignancies have an elevated risk of developing pneumonia after contracting COVID-19. Lymphoma is the most prevalent hematologic malignancy. It is critical to identify patients at high risk of contracting COVID-19-associated pneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From January 11\u201331, 2023, we distributed questionnaires to patients diagnosed with lymphoma according to 2016 World Health Organization diagnostic and classification criteria. COVID-19 infection was confirmed based on symptoms and laboratory tests. Pneumonia was confirmed using computed tomography scans.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 257 patients were included in this study; 221 patients (86.0%) had COVID-19 infection and 61 (27.6%) of these had pneumonia. Patients with B-cell non-Hodgkin lymphoma (B-NHL) had a significantly higher pneumonia incidence than patients with other lymphoma types (31.8% vs. 27.6%, P=0.005). Higher incidence of pneumonia was observed in patients receiving anti-CD20 therapy (30.0% vs. 16.3%, P=0.048) and Bruton\u2019s tyrosine kinase (BTK) inhibitor therapy (51.3% vs. 22.5%, P=0.001). B-NHL (hazard ratio [HR]=3.7, 95% confidence interval [CI] 1.4\u201310.0, P=0.009), anti-CD20 therapy (HR=2.3, 95% CI 1.0\u20135.2, P=0.050), BTK inhibitor (HR=3.6, 95% CI 1.8\u20137.4, P&amp;lt;0.001), active therapy (HR=3.0, 95% CI 1.5\u20135.7, P=0.001), and lack of disease remission (HR=3.7, 95% CI 1.8\u20137.4, P=0.001) were high-risk factors for developing pneumonia. Anti-PD-1 therapy was a protective factor against pneumonia development (HR=0.2, 95% CI 0.05\u20130.9, P=0.034). In multivariable analysis, BTK inhibitor (HR=3.5, 95% CI 1.6\u20138.0, P=0.003), active therapy (HR=3.3, 95% CI 1.6\u20136.8, P=0.001), and disease non-remission (HR=2.9, 1.3\u20136.4, P=0.007) were independent risk factors for pneumonia development after COVID-19 infection in patients with lymphoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with lymphoma receiving BTK inhibitors, undergoing active therapy, and lacking disease remission exhibited a higher risk for pneumonia associated with COVID-19.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1504809","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:03:06Z","timestamp":1736146986000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijie","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haichen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linna","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.v110.5","article-title":"Global reported impacts of COVID-19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic","volume":"110","author":"Elliott","year":"2023","journal-title":"Eur J Haematology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","article-title":"Impact of hematologic Malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study","volume":"13","author":"Garc\u00eda-Su\u00e1rez","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic Malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000538","article-title":"Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study","volume":"5","author":"Regalado-Artamendi","year":"2021","journal-title":"Hemasphere"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological Malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005691","article-title":"A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study","volume":"6","author":"Visco","year":"2022","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02484-x","article-title":"Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study","volume":"21","author":"Shu","year":"2024","journal-title":"Virol J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur Respir J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3157-9","article-title":"Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma","volume":"97","author":"Liu","year":"2018","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.v3.4","article-title":"Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial","volume":"3","author":"Zhu","year":"2022","journal-title":"EJHaem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.10.1002\/pds.1587","article-title":"Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab","volume":"17","author":"Gonzalez","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.006","article-title":"COVID-19 vaccination and breakthrough infections in patients with cancer","volume":"33","author":"Schmidt","year":"2022","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.01.035","article-title":"Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients","volume":"165","author":"Heudel","year":"2022","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.v96.11","article-title":"Serologic response to mRNA COVID-19 vaccination in lymphoma patients","volume":"96","author":"Jurgens","year":"2021","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013445","article-title":"Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients","volume":"139","author":"Liebers","year":"2022","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281902","article-title":"Antibody response after vaccination against SARS-CoV-2 in adults with hematological Malignancies: a systematic review and meta-analysis","volume":"108","author":"Shao","year":"2023","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","article-title":"Prolonged SARS-coV-2 infection in patients with lymphoid Malignancies","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discovery"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.55727","article-title":"COVID-19 in pediatric patients with acute lymphoblastic leukemia or lymphoma","volume":"7","author":"Hashmi","year":"2024","journal-title":"JAMA Network Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100549","DOI":"10.1016\/j.eclinm.2020.100549","article-title":"Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study","volume":"27","author":"Lamure","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006288","article-title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.995522","article-title":"Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database","volume":"13","author":"Wan","year":"2022","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13045-021-01174-3","article-title":"Zanubrutinib monotherapy in relapsed\/refractory mantle cell lymphoma: a pooled analysis of two clinical trials","volume":"14","author":"Zhou","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell Malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163567","article-title":"Weighted gene co-expression network analysis combined with machine learning validation to identify key modules and hub genes associated with SARS-CoV-2 infection","volume":"10","author":"Karami","year":"2021","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1504809\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:03:08Z","timestamp":1736146988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1504809\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":30,"alternative-id":["10.3389\/fonc.2024.1504809"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1504809","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"article-number":"1504809"}}